Accumulating evidence shows that hypoxia can hinder the success of androgen deprivation therapy (ADT) and AR inhibitors in AR growth-driven prostate cancers by increasing AR expression and/or activity and upregulating other compensatory signaling pathways to promote castration-resistant prostate cancer (CRPC) [19,20,21,22,23,24]. This evidence concerns the gene AR and prostate cancer.